A stem cell therapy conditionally approved in South Korea for treating amyotrophic lateral sclerosis (ALS) will remain available in…
Andrea Lobo, PhD
Andrea Lobo holds a PhD in cell biology/neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, including stroke, gene regulation, cancer, and rare diseases. She has authored multiple research papers in peer-reviewed journals.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Andrea Lobo, PhD
People with a history of smoking may face a higher risk of developing amyotrophic lateral sclerosis (ALS) than non-smokers, according…
A post-marketing analysis of safety reports found that many of the strongest signals involving Qalsody (tofersen) in people with…
The first patient has been dosed in a Phase 1/2 clinical trial evaluating Leal Therapeutics‘ LTX-002, an antisense oligonucleotide…
Nura Bio has raised $73.8 million to support two experimental therapies designed to protect nerve cells from…
Lower blood levels of adiponectin, a signaling molecule produced by fat tissue, and the anti-inflammatory molecule interleukin (IL)-10 are associated…
Neurosense Therapeutics said it recently held a “constructive” meeting with Health Canada to discuss potential regulatory pathways for PrimeC,…
PAS-004, an experimental therapy that Pasithea Therapeutics is developing to address inflammation and TDP-43 protein clumps, has received orphan…
Neurizon Therapeutics has received ethics approval for an Australia-based Phase 1 clinical trial that will test an oral liquid…
EverythingALS has launched a new online tool called SAVA AI that uses artificial intelligence to instantly match people with…